Financings

Beigene Ltd. said it plans to sell $125 million of its American depositary shares.

Biomarin Pharmaceutical Inc. disclosed an underwritten offering of $450 million aggregate principal amount of 0.599 percent senior subordinated convertible notes due 2024, granting the underwriters a 13-day option to purchase up to an additional $45 million more.

Dynavax Technologies Corp. priced its offering of 5 million shares of its common stock at $15 per share, providing gross proceeds of approximately $75 million.

Esperion Therapeutics Inc. said it priced its public offering of 3.1 million shares of its common stock at $49 per share, producing gross proceeds of $151.9 million.

Hangzhou Just Biotherapeutics Ltd. completed a $57 million series B round.

Radius Health Inc. priced $300 million aggregate principal amount of 3 percent convertible senior notes due 2024 in an underwritten public offering.

Roivant Sciences Inc., an umbrella for five biopharma companies, has secured biopharma's biggest-ever private financing, a $1.1 billion equity investment led by Softbank Vision Fund.

Spark Therapeutics Inc. closed its public offering netting the company $380.4 million.

Deals

Acella Pharmaceuticals LLC inked a multiproduct development and licensing partnership with Catalent Pharma Solutions to develop a portfolio of abuse-deterrent pain relief products.

Alexion Pharmaceuticals Inc. and Sema4 entered a strategic partnership to leverage their know-how in data science and systems biology to accelerate rare disease diagnosis and therapeutic discovery.

Alligator Bioscience AB expanded its immuno-oncology collaboration with Stanford University. The collaboration's objective is to enable the early prediction of clinical efficacy of Alligator's pipeline candidates through the analysis of potential systemic biomarkers.

Antriabio Inc. acquired the rights to Activesite Pharmaceuticals Inc.'s plasma kallikrein inhibitor program so it can develop, file, manufacture, market and sell products for diabetic macular edema and other conditions.

Dermira Inc. agreed to pay Roche Group up to $1.4 billion for global rights to the midstage interleukin-13 antagonist lebrikizumab for atopic dermatitis and other indications in hopes it will prove more effective than existing therapies, even with less frequent dosing.

Hitgen Ltd. entered a multitarget, multiyear collaboration with Leo Pharma A/S to discover small-molecule leads for multiple therapeutic targets of interest to Leo.

IFM Therapeutics Inc. has been acquired by Bristol-Myers Squibb Co. for $300 million up front and another $1.01 billion in potential development, regulatory and sales milestones for each of the first products from the deal's two oncology programs.

Mallinckrodt plc said it plans to acquire Infacare Pharmaceutical Corp., the developer of a late-stage severe jaundice treatment, for $80 million up front plus up to $345 million in potential milestone payments.

Melinta Therapeutics Inc. will merge with a subsidiary of Cempra Inc. in an all-stock transaction to create a stand-alone firm specializing in anti-infectives.

Takeda Pharmaceutical Co. Ltd., through its subsidiary, Millennium Pharmaceuticals Inc., formed a research collaboration with Shattuck Labs Inc. to explore and develop checkpoint fusion proteins as immunotherapies.

. . . And More

Applied Genetic Technologies Corp. was granted an FDA orphan drug designation for its gene therapy product candidate for the treatment of X-linked retinitis pigmentosa caused by mutations in the RPGR gene.

Australia's Therapeutic Goods Administration is asking for industry feedback on whether Australia should change its naming mechanisms for biosimilars and biologics and if it should adopt practices of other international regulators.

Glaxosmithkline plc will be shutting down operations at its Neuroscience R&D Centre in Shanghai and will move key programs to the global R&D hub in the U.S.

The Pew Charitable Trusts is stepping in to fill a gap in the international fight against antimicrobial resistance, with the formation of a virtual laboratory that will bring together disparate datasets and leading experts in an open platform for use by industry, academics and nonprofits.

Portola Pharmaceuticals Inc. resubmitted its FDA biologics license application for Andexxa (andexanet alfa), a reversal agent for factor Xa inhibitors.

The EMA has opened a public consultation on the development of drugs for use by older people who are at the greatest risk of encountering usability problems that can lead to poor adherence, medication errors and reduced quality of life.

Vernalis plc said the FDA issued a complete response letter for its NDA for cough and cold treatment CCP-08.